Skip header and navigation

1 records – page 1 of 1.

The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations.

https://arctichealth.org/en/permalink/ahliterature100913
Source
Vaccine. 2011 Jun 7;
Publication Type
Article
Date
Jun-7-2011
Author
Maria Said
Katherine L O'Brien
J Pekka Nuorti
Rosalyn Singleton
Cynthia G Whitney
Thomas W Hennessy
Author Affiliation
Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, 621N, Washington Street, Baltimore, MD 21205, United States.
Source
Vaccine. 2011 Jun 7;
Date
Jun-7-2011
Language
English
Publication Type
Article
Abstract
Alaska Native and some American Indian (AI/AN) populations suffer disproportionately high rates of invasive pneumococcal disease (IPD) in both the pediatric and adult populations compared to the general U.S. population. Two pneumococcal vaccines are currently available in the U.S.: a 23-valent pneumococcal polysaccharide vaccine (PPSV23), available since 1983 and recommended for the elderly and those over 2 years of age with underlying medical conditions, and a 13-valent pneumococcal conjugate vaccine (PCV13), used in the routine infant immunization schedule since 2010. The U.S. Advisory Committee on Immunization Practice (ACIP) previously recommended use of PPSV23 for persons living in special environments or social settings, including AN and certain AI persons 2-64 years of age, on the basis of higher disease rates. The recommendation for routine PPSV23 use among AI/AN persons
PubMed ID
21664217 View in PubMed
Less detail